Cargando…

Circulating microRNAs as novel biomarkers of ALK-positive non-small cell lung cancer and predictors of response to crizotinib therapy

Circulating microRNAs are potential diagnostic and predictive biomarkers, but have not been investigated for patients with anaplastic lymphoma kinase (ALK)-positive lung cancer. In this exploratory study, we sought to identify potential plasma biomarkers for ALK-positive non-small cell lung cancer (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Liang-Liang, Qu, Li-Li, Fu, Han-Jiang, Zheng, Xiao-Fei, Tang, Chuan-Hao, Li, Xiao-Yan, Chen, Jian, Wang, Wei-Xia, Yang, Shao-Xing, Wang, Lin, Zhao, Guan-Hua, Lv, Pan-Pan, Zhang, Min, Lei, Yang-Yang, Qin, Hai-Feng, Wang, Hong, Gao, Hong-Jun, Liu, Xiao-Qing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542196/ https://www.ncbi.nlm.nih.gov/pubmed/28514730 http://dx.doi.org/10.18632/oncotarget.17535

Ejemplares similares

Favorable predictors for survival in advanced ALK‐positive non‐small cell lung cancer patients beyond crizotinib resistance
por: Xu, Haiyan, et al.
Publicado: (2019)

Clinical features and outcomes of ALK rearranged non‐small cell lung cancer with primary resistance to crizotinib
por: Ma, Di, et al.
Publicado: (2019)

Lung adenocarcinoma harboring concomitant SPTBN1-ALK fusion, c-Met overexpression, and HER-2 amplification with inherent resistance to crizotinib, chemotherapy, and radiotherapy
por: Gu, Fei-fei, et al.
Publicado: (2016)

CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib
por: Du, Xue, et al.
Publicado: (2018)

High Tumor Mutation Burden and DNA Repair Gene Mutations are Associated with Primary Resistance to Crizotinib in ALK-Rearranged Lung Cancer
por: Xiao, Dakai, et al.
Publicado: (2021)

MicroRNAs in heart and circulation during physical exercise
por: Wang, Lijun, et al.
Publicado: (2018)

Heterogeneous responses and resistant mechanisms to crizotinib in ALK‐positive advanced non‐small cell lung cancer
por: Kang, Jin, et al.
Publicado: (2018)

Crizotinib in Sarcomatous Malignancies Harboring ALK Fusion With a Definitive Partner(s): Response and Efficacy
por: Wu, Jinchun, et al.
Publicado: (2021)

Clinical Benefit From a Combination of Brigatinib and Camrelizumab in Sarcomatoid Transformation of ALK-Rearranged Squamous Cell Lung Cancer Resistant to Crizotinib
por: Jiang, Wei, et al.
Publicado: (2020)

Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis
por: Wang, Yongfeng, et al.
Publicado: (2016)

Impact of crizotinib on long-term survival of ALK-positive advanced non-small-cell lung cancer: A Chinese multicenter cohort study
por: Xing, Puyuan, et al.
Publicado: (2019)

Dual drive coexistence of ALK rearrangement and KRAS mutation advanced lung adenocarcinoma and response to crizotinib
por: Zhu, You-Cai, et al.
Publicado: (2019)

PET-CT evaluation of the curative effect of crizotinib on malignant myofibroblastoma with rare mutation of ALK R401: a case report and literature review
por: Yang, Li, et al.
Publicado: (2018)

Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively
por: Tao, Hong, et al.
Publicado: (2022)

Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression
por: Chen, Rui-Lian, et al.
Publicado: (2018)

ALK-driven tumors and targeted therapy: focus on crizotinib
por: Murga-Zamalloa, Carlos, et al.
Publicado: (2014)

Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with ALK mutation
por: Ogata, Misato, et al.
Publicado: (2018)

LMO7-ALK Fusion in a Lung Adenocarcinoma Patient With Crizotinib: A Case Report
por: Yang, Yanlong, et al.
Publicado: (2022)

Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK wild-type advanced non-small cell lung cancer
por: Peng, Xiao-Xiao, et al.
Publicado: (2020)

A Rare STRN-ALK Fusion in Lung Adenocarcinoma Identified Using Next-Generation Sequencing–Based Circulating Tumor DNA Profiling Exhibits Excellent Response to Crizotinib
por: Yang, Yan, et al.
Publicado: (2017)

Simultaneous VENTANA IHC and RT-PCR testing of ALK status in Chinese non-small cell lung cancer patients and response to crizotinib
por: Xu, Chun-wei, et al.
Publicado: (2018)

Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib
por: Liang, Hongge, et al.
Publicado: (2019)

L1198F Mutation Resensitizes Crizotinib to ALK by Altering the Conformation of Inhibitor and ATP Binding Sites
por: Li, Jian, et al.
Publicado: (2017)

Case Report: Neoadjuvant and Adjuvant Crizotinib Targeted Therapy in Stage IIIA-N2 ALK-Positive Non-Small-Cell Lung Cancer
por: Xie, Xiao-Hong, et al.
Publicado: (2021)

Circulating microRNAs as mirrors of acute coronary syndromes: MiRacle or quagMire?
por: Li, Jin, et al.
Publicado: (2013)

Coexistence of a novel CCNY-ALK and ATIC-ALK double-fusion in one patient with ALK-positive NSCLC and response to crizotinib: a case report
por: Wu, Xuan, et al.
Publicado: (2020)

Crizotinib Exhibits Antitumor Activity by Targeting ALK Signaling not c-MET in Pancreatic Cancer
por: Yan, Hong Hua, et al.
Publicado: (2014)

ALK-rearranged lung adenocarcinoma patient with development of severe sinus bradycardia after treatment with crizotinib: A case report
por: Qiu, Ye, et al.
Publicado: (2019)

Alectinib versus crizotinib in ALK‐positive advanced non‐small cell lung cancer and comparison of next‐generation TKIs after crizotinib failure: Real‐world evidence
por: Wang, Yurong, et al.
Publicado: (2022)

Circulating microRNAs Serve as Novel Biological Markers for Intracranial Aneurysms
por: Li, Pengxiang, et al.
Publicado: (2014)

Identification of Long Noncoding RNAs as Predictors of Survival in Triple-Negative Breast Cancer Based on Network Analysis
por: Li, Xiao-Xiao, et al.
Publicado: (2020)

A case of large-cell neuroendocrine carcinoma harboring rare ALK fusion with initial response to the ALK inhibitor crizotinib and acquired F1174L mutation after resistance
por: Wang, Ye, et al.
Publicado: (2019)

Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK‐rearranged non‐small‐cell lung cancer
por: Song, Peng, et al.
Publicado: (2019)

Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative
por: Ma, Di, et al.
Publicado: (2016)

Hexokinases II‐mediated glycolysis governs susceptibility to crizotinib in ALK‐positive non‐small cell lung cancer
por: Lin, Caiyu, et al.
Publicado: (2021)

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
por: Fontana, Diletta, et al.
Publicado: (2015)

A rare double ALK fusion variant EML4-ALK and CDK15-ALK in lung adenocarcinoma and response to crizotinib: A case report
por: Guo, Jun, et al.
Publicado: (2020)

Comparison of Next-Generation Sequencing and Ventana Immunohistochemistry in Detecting ALK Rearrangements and Predicting the Efficacy of First-Line Crizotinib in Patients with Advanced Non-Small Cell Lung Cancer
por: Zeng, Liang, et al.
Publicado: (2020)

ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance
por: Ye, Mingxiang, et al.
Publicado: (2016)

A novel GHR-ALK fusion gene in a patient with metastatic lung adenocarcinoma and its response to crizotinib: a case report
por: Pan, Xue, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f01glo0of859cjc95ooqj5nnnf